Literature DB >> 23529583

Infectious complications in juvenile idiopathic arthritis.

Andrew Hurd1, Timothy Beukelman.   

Abstract

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood. Many questions regarding the risk of infection associated with JIA and with the immunosuppressant therapeutic agents commonly used to treat JIA are currently unanswered. It appears likely that JIA itself increases the background rate of serious bacterial infections, irrespective of immunosuppressant use. The available evidence suggests that treatment with methotrexate or tumor necrosis factor inhibitors only modestly increases the risk of serious infections and may not increase the risk at all. Opportunistic infections are very uncommon among children with JIA, but they likely occur at an increased rate compared to children without JIA. Intra-articular glucocorticoid injections almost never result in infectious complications in the treatment of JIA when performed carefully. Additional controlled studies of the risks of infection among children with JIA are needed, particularly comparative studies of newer therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529583     DOI: 10.1007/s11926-013-0327-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  46 in total

1.  Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry.

Authors:  Meredith Y Smith; Rachel E Sobel; Carol A Wallace
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

2.  TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis.

Authors:  Michael A Lane; Jay R McDonald; Angelique L Zeringue; Liron Caplan; Jeffrey R Curtis; Prabha Ranganathan; Seth A Eisen
Journal:  Medicine (Baltimore)       Date:  2011-03       Impact factor: 1.889

3.  Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.

Authors:  Gecilmara Salviato Pileggi; Cleonice Barbosa Sandoval de Souza; Virgínia Paes Leme Ferriani
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

Review 4.  Juvenile idiopathic arthritis.

Authors:  Berent Prakken; Salvatore Albani; Alberto Martini
Journal:  Lancet       Date:  2011-06-18       Impact factor: 79.321

5.  The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.

Authors:  Jeffrey R Curtis; Fenglong Xie; Lang Chen; John W Baddley; Timothy Beukelman; Kenneth G Saag; Claire Spettell; Raechele M McMahan; Joaquim Fernandes; Kevin Winthrop; Elizabeth Delzell
Journal:  Ann Rheum Dis       Date:  2011-05-17       Impact factor: 19.103

Review 6.  Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations.

Authors:  M W Heijstek; L M Ott de Bruin; R Borrow; F van der Klis; I Koné-Paut; A Fasth; K Minden; A Ravelli; M Abinun; G Pileggi; M Borte; M Bijl; N M Wulffraat
Journal:  Autoimmun Rev       Date:  2011-08-28       Impact factor: 9.754

7.  Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.

Authors:  Marloes W Heijstek; Gecilmara C S Pileggi; Evelien Zonneveld-Huijssoon; Wineke Armbrust; Esther P A H Hoppenreijs; Cuno S P M Uiterwaal; Wietse Kuis; Nico M Wulffraat
Journal:  Ann Rheum Dis       Date:  2007-02-06       Impact factor: 19.103

8.  Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.

Authors:  G Horneff; F De Bock; I Foeldvari; H J Girschick; H Michels; D Moebius; H Schmeling
Journal:  Ann Rheum Dis       Date:  2008-04-15       Impact factor: 19.103

9.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Authors:  Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini
Journal:  Lancet       Date:  2008-07-14       Impact factor: 79.321

10.  Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Authors:  Daniel J Lovell; Nicolino Ruperto; Steven Goodman; Andreas Reiff; Lawrence Jung; Katerina Jarosova; Dana Nemcova; Richard Mouy; Christy Sandborg; John Bohnsack; Dirk Elewaut; Ivan Foeldvari; Valeria Gerloni; Jozef Rovensky; Kirsten Minden; Richard K Vehe; L Wagner Weiner; Gerd Horneff; Hans-Iko Huppertz; Nancy Y Olson; John R Medich; Roberto Carcereri-De-Prati; Melissa J McIlraith; Edward H Giannini; Alberto Martini
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

View more
  8 in total

1.  A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors.

Authors:  Heather M Walters; Nancy Pan; Thomas J A Lehman; Alexa Adams; Wei-Ti Huang; Lemonia Sitaras; Susanna Cunningham-Rundles; Thomas J Walsh; Sima S Toussi
Journal:  Clin Rheumatol       Date:  2014-09-18       Impact factor: 2.980

2.  Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.

Authors:  Rebecca Davies; Taunton R Southwood; Lianne Kearsley-Fleet; Mark Lunt; Kimme L Hyrich
Journal:  Arthritis Rheumatol       Date:  2015-09       Impact factor: 10.995

3.  Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.

Authors:  Joost Swart; Gabriella Giancane; Gerd Horneff; Bo Magnusson; Michael Hofer; Еkaterina Alexeeva; Violeta Panaviene; Brigitte Bader-Meunier; Jordi Anton; Susan Nielsen; Fabrizio De Benedetti; Sylvia Kamphuis; Valda Staņēviča; Maria Tracahana; Laura Marinela Ailioaie; Elena Tsitsami; Ariane Klein; Kirsten Minden; Ivan Foeldvari; Johannes Peter Haas; Jens Klotsche; Anna Carin Horne; Alessandro Consolaro; Francesca Bovis; Francesca Bagnasco; Angela Pistorio; Alberto Martini; Nico Wulffraat; Nicolino Ruperto
Journal:  Arthritis Res Ther       Date:  2018-12-27       Impact factor: 5.156

Review 4.  The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis.

Authors:  Arnold Nagy; Péter Mátrai; Péter Hegyi; Hussain Alizadeh; Judit Bajor; László Czopf; Zoltán Gyöngyi; Zoltán Kiss; Katalin Márta; Mária Simon; Ágnes Lilla Szilágyi; Gábor Veres; Bernadett Mosdósi
Journal:  Pediatr Rheumatol Online J       Date:  2019-01-18       Impact factor: 3.054

5.  Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.

Authors:  Franz Thiele; Ariane Klein; Daniel Windschall; Anton Hospach; Ivan Foeldvari; Kirsten Minden; Frank Weller-Heinemann; Gerd Horneff
Journal:  Rheumatol Int       Date:  2021-02-16       Impact factor: 2.631

6.  Peripheral Blood Lymphocyte Analysis in Oligo- and Polyarticular Juvenile Idiopathic Arthritis Patients Receiving Methotrexate or Adalimumab Therapy: A Cross-Sectional Study.

Authors:  Arnold Nagy; Bernadett Mosdosi; Diana Simon; Timea Dergez; Timea Berki
Journal:  Front Pediatr       Date:  2020-12-10       Impact factor: 3.418

7.  Are infections in children with juvenile idiopathic arthritis more frequent than in healthy children? A prospective multicenter observational study.

Authors:  Clara Udaondo; Esmeralda Núñez Cuadros; Sara Murias; Agustin Remesal; Rosa Alcobendas; Concepción Guerrero; Sara Guillen-Martin; Marta Escuredo; Esther Aleo; Daniel Alonso; Alfredo Tagarro; Eloisa De Santiago; Marisol Camacho-Lovillo; Fatima Diaz; Dolores Arenas; Pilar Camacho; Maria Jose Lirola; Mariana Díaz Almirón; Cristina Calvo
Journal:  Front Pediatr       Date:  2022-08-11       Impact factor: 3.569

8.  The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.

Authors:  Timothy Beukelman; Fenglong Xie; John W Baddley; Lang Chen; Melissa L Mannion; Kenneth G Saag; Jie Zhang; Jeffrey R Curtis
Journal:  Arthritis Res Ther       Date:  2016-09-22       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.